TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Making changes in physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Lung Ultrasound score variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Lung Ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Not aerated tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Sleep Time Coefficient of Variation (TST-CV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain rating decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reporting 'completely recovered' or 'much improved'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean global health status quality-of-life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: patients' subjective judgment of comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dysphagia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time until definitive deterioration for appetite loss
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time until definitive deterioration for QLQ-OES-18 pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relative risk of total mortality
Endpoint domain: Mortality/survival
Primary endpoint: Absolute 4-year mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: Projected additional years of life
Endpoint domain: Mortality/survival
Primary endpoint: modelled CVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for ventilatory manipulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative hemodynamics (diastolic blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CDR-SB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postoperative infections
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbial eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of shunt infection
Endpoint domain: Adverse events/effects
Primary endpoint: Decline in FEV1 and FVC bronchodilator responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Factor VIII:C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient tolerance to FB
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of inflammatory cytokines (IL-6, IL-17, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of vascular endothelial growth factor (VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FP C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FP AUC(0,t(last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shin‐Hur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalisation duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Recession (REC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of IL-6 and hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fat mass percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post‐bronchodilator FEV(1)%p
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of ED admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sensitivity of glaucoma screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of glaucoma screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of glaucoma screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-efficacy for participating in osteoporosis prevention and treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum plasma concentration of S‐1452
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory effect on platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: duration of satisfactory analgesia prior to re-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conduction speed of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delay in gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax for nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of IGD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of intrapersonal and interpersonal abilities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of family relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in behavior and executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Effect (TE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-monitoring of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to HPV 6/11/16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response to HPV 31/33/45/52/58
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of injection-site swelling
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in frequency and intensity of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved sleep pattern
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: wound healing complications
Endpoint domain: Adverse events/effects
Primary endpoint: HDL phospholipid content enrichment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differentiation of relapses and reinfections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: positive experiences of caregiving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PSADT lengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival rate at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Foot temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Core temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF concentration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients completing six cycles without dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing grade III/IV adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Wake time after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Autobiographical memory consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery on the Borderline Personality Disorder Severity Index
Endpoint domain: Mortality/survival
Primary endpoint: Reliable clinical improvement on the Borderline Personality Disorder Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bioavailability (%F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of blood contamination of the hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: voice-impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of catheter-related contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: New heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total satisfactory degree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation with coronary score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time taken for stress test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: first major vascular event
Endpoint domain: Mortality/survival
Primary endpoint: Need for further downstream testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NMD (Nitroglycerin-mediated dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: fasting insulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of eyes with visual loss >/=0.1 logMAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity measured by active MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time below 3.9 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviation of blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on extracorporeal circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to recovery (TOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral to lifestyle intervention program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Albumin fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin absolute synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratio of omeprazole to 5‐hydroxyomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in constipation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: composite prolapse outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine concentrations needed to induce bronchial obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of positive results after exercise-induced stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS in recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change of alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: striatum (123)I-FP-CIT binding ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to removal of chest tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median plasma viral RNA levels decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median CD4+ cell count increased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: distal urethral closure pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Valuations of health states
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: level of cognitive activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent reduction in left ventricular end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of heart failure or death
Endpoint domain: Mortality/survival
Primary endpoint: Decision to take antihypertensive medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of significant intracranial hemorrhage (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in fellow eye amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of residual grafted material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of marrow spaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SWN scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mucosal erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of appliances
Endpoint domain: Adverse events/effects
Primary endpoint: binocular uncorrected distance visual acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binocular uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periprocedural myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADL Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fridericia's corrected QT interval (ΔQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life years (QALYs) gained
Endpoint domain: Life impact
Primary endpoint: HOMA-IR association with bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in right ventricle free wall peak velocity E'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in peak velocity A'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic levels of LPV in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of LPV in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant exposure to NVP, ABC, ZDV and 3TC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in serum HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody level against HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy lifestyle beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incremental life year
Endpoint domain: Mortality/survival
Primary endpoint: Quality-adjusted life year gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrement in serum fetuin-A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short‐term clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long‐term clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospital charges saved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean pulsatility index in fetal ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: FDD of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sTNFR1 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sTNFR2 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound infections requiring prolonged antibiotics use or surgical debridement
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of radiation-induced skin injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Participant truthfulness in reporting behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scores on clinician-rated depression and anxiety scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on self-rated depression, anxiety, and somatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔR30 plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of mean NIHSS score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of favourable outcome at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median time to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EL positive cell rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of main conjunctivitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hole enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opening urethral pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year progression-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Control of symptoms and exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of recurrent instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative plasma sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in psoriatic arthropathy adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in psoriasis/psoriatic arthritis-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Requirements for antiemetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of total ventilated time breathing in synchrony with ventilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic permeability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AMP PD20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean values of μTBS (in MPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of bowel movements per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes